Oncotalks hematology videos and news

EHA 2019 Prof. James Bussel, MD - LONG-TERM OVERUSE OF CORTICOSTEROIDS IN THE REAL-WORLD TREATMENT OF PATIENTS WITH ITP

Prof. James Bussel, MD from the Well Cornel Medicine, New York, USA is commenting on the abstract LONG-TERM OVERUSE OF CORTICOSTEROIDS IN THE REAL-WORLD TREATMENT OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA IN THE US EXPLORYS AND MARKETSCAN DATABASES which he presented at EHA 2019 in Amsterdam

Reference: EHA Library. Bussel J. Jun 14, 2019; 266509

Link to abstract: https://library.ehaweb.org/eha/2019/24th/266509/j.bussel.long-term.overuse.of.corticosteroids.in.the.real-world.treatment.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DLONG-TERM+OVERUSE+OF+CORTICOSTEROIDS+IN+THE+REAL-WORLD+TREATMENT+OF+PATIENTS+WITH+IMMUNE+THROMBOCYTOPENIA+IN+THE+US+EXPLORYS+AND+MARKETSCAN+DATABASES

Related items

EHA 2019 Jeroen Janssen, MD, PhD

EHA 2019 Jeroen Janssen, MD, PhD

Jeroen Janssen MD, PhD from the Amsterdam UMC, Amsterdam, The Netherlands is commenting on the abstract COMBINATION THERAPY USING ASCIMINIB PLUS IMATINIB (IMA) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML) & COMBINATION OF ASCIMINIB PLUS NILOTINIB (NIL) OR DASATINIB (DAS) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA Reference: EHA Library. Kew S. Jun 15, 2019; 267467Link to abstract: https://library.ehaweb.org/eha/2019/24th/267467/sam.kew.combination.of.asciminib.plus.nilotinib.28nil29.or.dasatinib.28das29.in.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dasciminib
EHA , Latvia , Lithuania , Estonia , Albania
00:05:04
EHA 2019 Prof. Heinz Gisslinger, MD

EHA 2019 Prof. Heinz Gisslinger, MD

Prof. Heinz Gisslinger, MD Medical University of Vienna, Vienna, Austria commenting on REAL-WORLD SAFETY DATA FROM A NONINTERVENTIONAL LONG-TERM POSTAUTHORIZATION SAFETY STUDY OF RUXOLITINIB IN MYELOFIBROSIS which was presented at EHA 2019 in AmsterdamReferences: EHA Library. BARRACO F. Jun 14, 2019; 266478Link to abstract: https://library.ehaweb.org/eha/2019/24th/266478/fiorenza.barraco.real-world.safety.data.from.a.noninterventional.long-term.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DREAL-WORLD+SAFETY+DATA+FROM+A+NONINTERVENTIONAL+LONG-TERM+POSTAUTHORIZATION+SAFETY+STUDY+OF+RUXOLITINIB+IN+MYELOFIBROSIS
EHA , Lithuania , Albania
00:04:02
EHA 2019 Chinmay Munje, MD, PhD

EHA 2019 Chinmay Munje, MD, PhD

Chinmay Munje, MD, PhD from the Paul O’Gorman Leukaemia Research Centre, Glasgow, UK is commenting on the publication "COMBINATION OF ASCIMINIB (ABL001) WITH ATP-COMPETITIVE TYROSINE KINASE INHIBITORS TARGETS EARLY CML PROGENITOR CELLS", which was presented at EHA 2019 in AmsterdamReference: EHA Library. BARRACO F. Jun 14, 2019; 266478https://library.ehaweb.org/eha/2019/24th/266478/fiorenza.barraco.real-world.safety.data.from.a.noninterventional.long-term.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DREAL-WORLD+SAFETY+DATA+FROM+A+NONINTERVENTIONAL+LONG-TERM+POSTAUTHORIZATION+SAFETY+STUDY+OF+RUXOLITINIB+IN+MYELOFIBROSIS
EHA , Lithuania , Albania
00:04:34